Mira Pharmaceuticals, Inc. (MIRA) — 8-K Filings

8-K Filings (50)

• 8-K Filing — Dec 22, 2025
• 8-K Filing — Dec 5, 2025
• Mira Pharmaceuticals Files 8-K: Other Event — Oct 23, 2025 Risk: medium
  Mira Pharmaceuticals, Inc. filed an 8-K on October 23, 2025, reporting an "Other Event." The filing does not contain specific details about the event, its finan
• Mira Pharmaceuticals Files 8-K — Oct 16, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on October 16, 2025, reporting an "Other Events" item. The filing does not contain specific details about the event itse
• Mira Pharmaceuticals Files 8-K: Other Events — Oct 15, 2025 Risk: medium
  Mira Pharmaceuticals, Inc. filed an 8-K on October 15, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these ev
• Mira Pharmaceuticals Completes Acquisition, Reports Key Agreements — Sep 30, 2025 Risk: medium
  Mira Pharmaceuticals, Inc. announced on September 29, 2025, the completion of an acquisition. The company also reported on the entry into a material definitive
• Mira Pharmaceuticals Files 8-K — Sep 22, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on September 22, 2025, reporting an event under "Other Events." The company, formerly known as Mira1a Therapeutics, Inc.
• Mira Pharmaceuticals Files 8-K for Other Events — Sep 15, 2025 Risk: medium
  Mira Pharmaceuticals, Inc. filed an 8-K on September 15, 2025, reporting "Other Events." The company, formerly known as Mira1a Therapeutics, Inc. until January
• Mira Pharmaceuticals Files 8-K on Officer/Director Changes — Sep 11, 2025 Risk: medium
  Mira Pharmaceuticals, Inc. filed an 8-K on September 11, 2025, reporting on several key events. These include the departure of directors or certain officers, th
• Mira Pharmaceuticals Files 8-K for Other Events — Aug 19, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on August 19, 2025, to report other events. The company, formerly known as Mira1a Therapeutics, Inc. until January 12, 2
• Mira Pharmaceuticals Changes Principal Executive Offices — Aug 12, 2025 Risk: low
  On August 12, 2025, Mira Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1200 Brickell
• Mira Pharmaceuticals Files 8-K — Jul 29, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on July 29, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the event,
• Mira Pharmaceuticals Files 8-K — Jul 28, 2025 Risk: medium
  Mira Pharmaceuticals, Inc. filed an 8-K on July 28, 2025, reporting an event under "Other Events." The company, formerly known as Mira1a Therapeutics, Inc. sinc
• Mira Pharmaceuticals Files 8-K — Jul 10, 2025 Risk: low
  On July 10, 2025, Mira Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are located at 1200 Bricke
• Mira Pharmaceuticals to Acquire BioGenetics, Inc. — Jul 8, 2025 Risk: medium
  Mira Pharmaceuticals, Inc. announced on July 3, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of BioGenetics
• Mira Pharmaceuticals Updates Office and Contact Info — Jul 2, 2025 Risk: low
  On July 2, 2025, Mira Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1200 Brickell Ave
• Mira Pharmaceuticals Files 8-K — Jun 30, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on June 30, 2025, reporting an event under 'Other Events'. The company, formerly known as Mira1a Therapeutics, Inc. unti
• Mira Pharmaceuticals Files 8-K: Other Event — Jun 24, 2025 Risk: medium
  Mira Pharmaceuticals, Inc. filed an 8-K on June 24, 2025, reporting an "Other Event." The filing does not contain specific details about the event, its financia
• Mira Pharmaceuticals Files 8-K — Jun 17, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on June 17, 2025, reporting an "Other Events" item. The company, formerly known as Mira1a Therapeutics, Inc. until Janua
• Mira Pharmaceuticals Updates Office and Contact Info — May 28, 2025 Risk: low
  On May 28, 2025, Mira Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1200 Brickell Ave
• Mira Pharmaceuticals Reports Material Agreement, Officer Changes — May 21, 2025 Risk: medium
  On May 15, 2025, Mira Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
• Mira Pharmaceuticals Updates Office and Contact Info — May 8, 2025 Risk: low
  On May 8, 2025, Mira Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1200 Brickell Aven
• Mira Pharmaceuticals Relocates HQ — May 6, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on May 6, 2025, reporting an "Other Events" item. The filing indicates a change in the company's principal executive off
• Mira Pharmaceuticals Relocates Executive Offices — Apr 23, 2025 Risk: low
  On April 23, 2025, Mira Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1200 Brickell A
• Mira Pharmaceuticals Files 8-K — Apr 16, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on April 16, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the event
• Mira Pharmaceuticals Faces Delisting Concerns — Apr 11, 2025 Risk: high
  Mira Pharmaceuticals, Inc. filed an 8-K on April 11, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly
• Mira Pharmaceuticals Files 8-K — Apr 1, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on April 1, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but i
• Mira Pharmaceuticals Enters Material Definitive Agreement — Mar 24, 2025 Risk: medium
  Mira Pharmaceuticals, Inc. announced on March 19, 2025, that it entered into a material definitive agreement. The company, formerly known as Mira1a Therapeutics
• Mira Pharmaceuticals Relocates Principal Executive Offices — Mar 13, 2025 Risk: low
  On March 13, 2025, Mira Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1200 Brickell A
• Mira Pharmaceuticals Relocates HQ — Mar 4, 2025 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on March 4, 2025, reporting "Other Events." The filing indicates a change in the company's principal executive offices t
• Mira Pharmaceuticals Appoints BDO USA as New Auditor — Dec 20, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on December 16, 2024, that it has appointed BDO USA, P.A. as its new independent registered public accounting firm. This ch
• Mira Pharmaceuticals Files 8-K — Dec 19, 2024 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on December 19, 2024, reporting other events. The company, formerly known as Mira1a Therapeutics, Inc. until January 12,
• Mira Pharmaceuticals Files 8-K — Dec 10, 2024 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on December 10, 2024, to report other events. The company, formerly known as Mira1a Therapeutics, Inc. until January 12,
• Mira Pharmaceuticals Announces Board and Executive Changes — Nov 21, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on November 18, 2024, a change in its board of directors and executive compensation arrangements. The filing details the de
• Mira Pharmaceuticals to Acquire BioGenetics — Nov 19, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on November 19, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of BioGen
• Mira Pharmaceuticals to Acquire Private Company — Oct 25, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on October 25, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of a priva
• Mira Pharmaceuticals Files 8-K — Oct 21, 2024 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on October 21, 2024, reporting other events. The company, formerly known as Mira1a Therapeutics, Inc. since January 12,
• Mira Pharmaceuticals Files 8-K on Shareholder Vote Matters — Sep 12, 2024 Risk: low
  Mira Pharmaceuticals, Inc. filed an 8-K on September 12, 2024, to report on a submission of matters to a vote of security holders. The company, formerly known a
• Mira Pharmaceuticals Updates Corporate Address and Phone — Sep 10, 2024 Risk: low
  On September 10, 2024, Mira Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 1200 Bricke
• Mira Pharmaceuticals Files 8-K: $1.5M Stock Sale & Nasdaq Bid Price Notice — Aug 23, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on August 23, 2024, that it entered into a securities purchase agreement on August 20, 2024, to issue and sell approximatel
• Mira Pharmaceuticals to Acquire BioGenetics, Inc. — Aug 9, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on August 9, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of common stock of Bio
• Mira Pharmaceuticals Relocates Principal Executive Offices — Aug 8, 2024 Risk: low
  On August 7, 2024, Mira Pharmaceuticals, Inc. announced a change in its principal executive offices. The company is relocating its principal executive offices f
• Mira Pharmaceuticals to Acquire BioGenetics, Inc. — Jul 24, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on July 24, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests of BioGenetic
• Mira Pharmaceuticals to Acquire Bio-Genetics, Inc. — Jul 19, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on July 19, 2024, that it has entered into a definitive agreement to acquire all outstanding equity interests in Bio-Geneti
• Mira Pharmaceuticals Faces Nasdaq Delisting Concerns — Jul 12, 2024 Risk: high
  Mira Pharmaceuticals, Inc. announced on July 12, 2024, that it received a notice from the Nasdaq Stock Market on July 8, 2024, indicating non-compliance with li
• Mira Pharmaceuticals Appoints New Chief Medical Officer — Jun 28, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on June 28, 2024, the appointment of Dr. Jonathan L. Cohen as Chief Medical Officer, effective June 24, 2024. Dr. Cohen bri
• Mira Pharmaceuticals Adds New Director, Dr. Jianjun Li — May 29, 2024 Risk: low
  Mira Pharmaceuticals, Inc. announced on May 29, 2024, the election of Dr. Jianjun "James" Li as a new director and the appointment of Dr. Li as the Chair of the
• Mira Pharmaceuticals Appoints New Chief Medical Officer — Mar 13, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on March 13, 2024, that its Board of Directors appointed Dr. Jonathan L. Cohen as Chief Medical Officer, effective March 7,
• Mira Pharmaceuticals to Acquire NovaLead Pharma — Mar 7, 2024 Risk: medium
  Mira Pharmaceuticals, Inc. announced on March 7, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of NovaLead Pharma Ltd.
• MIRA PHARMACEUTICALS: Leadership & Compensation Changes Reported — Jan 17, 2024
  MIRA PHARMACEUTICALS, INC. filed an 8-K on January 17, 2024, reporting an event that occurred on January 15, 2024, related to changes in directors or officers a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX